Product information

From Health Canada

New search

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2006-03-24

Original market date: See footnote 1

2002-12-02

Product name:

VARIVAX III

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section .

DIN:

02246081

Product Monograph/Veterinary Labelling:

Date: 2020-11-17 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company: 

MERCK CANADA INC
16750 Route Transcanadienne
Kirkland
Quebec
Canada  H9H 4M7

Class: 

Human

Dosage form(s):

Powder For Solution

Route(s) of administration:

Subcutaneous

Number of active ingredient(s):

1

Schedule(s):

Schedule D  

Biosimilar Biologic Drug:

No

American Hospital Formulary Service (AHFS): See footnote 3

80:12.00   VACCINES

Anatomical Therapeutic Chemical (ATC): See footnote 4

J07BK01  VARICELLA, LIVE ATTENUATED

Active ingredient group (AIG) number:See footnote 5

0152480002

List of active ingredient(s)
Active ingredient(s) Strength
VARICELLA-ZOSTER VIRUS VACCINE LIVE ATTENUATED (OKA/MERCK STRAIN) 1350 UNIT / 0.5 ML

Application information

Related information

Contact us

Version 3.8.0
Date modified: